Diagnostic Approach and Treatment for Suspected Aspergilloma

Initial Diagnostic Approach

The European Respiratory Society recommends an initial diagnostic approach for a patient suspected of having an aspergilloma, including chest CT scan and serological testing for Aspergillus antibodies, followed by bronchoscopy with bronchoalveolar lavage if clinically indicated 1, 2

Chest radiographs are the first imaging modality for initial suspicion, but have limited sensitivity 1
The European Respiratory Society strongly recommends chest CT scan (preferably high-resolution CT) as the primary imaging modality for diagnosis, with superior definition of abnormalities 1, 2
Intravenous contrast administration (CT angiography) is required at baseline to evaluate vascular structures, especially if hemoptysis is present 1, 3
Positron emission tomography (PET) is not useful for diagnosis as aspergillosis can cause false-positive results not attributable to malignancy 1

The European Respiratory Society strongly recommends Aspergillus IgG antibody testing with high sensitivity (>90%) for diagnosis 1, 4
Aspergillus precipitins testing is also recommended but has uncertain sensitivity 1
Direct microscopy of respiratory specimens using fluorescent dyes (Calcofluor White or Blancophor) increases sensitivity for fungal elements 3
Culture of respiratory specimens on specific fungal media should be performed, with species identification to complex level for clinically relevant isolates 3

The Infectious Diseases Society of America strongly recommends bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspected aspergilloma 2, 3
BAL samples should be sent for routine culture, cytology, and non-culture-based methods such as galactomannan testing 2

The European Respiratory Society recommends surgical excision as the treatment of choice for simple aspergilloma if technically feasible and if the patient can tolerate the procedure 4, 5
Video-assisted thoracic surgery (VATS) technique is preferred when possible 4
Surgical resection is strongly recommended for patients with symptoms, especially significant hemoptysis 5

The Infectious Diseases Society of America recommends long-term oral antifungal therapy with triazoles for complex aspergilloma or when surgery is not feasible 4, 5
Voriconazole is the preferred first-line agent for treatment 5
Therapeutic drug monitoring is strongly recommended for patients receiving voriconazole to optimize efficacy and minimize toxicity 6

The Infectious Diseases Society of America recommends oral tranexamic acid for management of hemoptysis 5
Bronchial artery embolization is strongly recommended for severe hemoptysis 5
Antifungal therapy should be used to prevent recurrence of hemoptysis 5

The European Respiratory Society recommends follow-up chest CT scan after a minimum of 2-3 months of treatment to assess response 1, 2
Monitoring of azole serum concentrations, drug interactions, and toxicities is recommended during long-term therapy 4
In patients with progressive disease, long-term or even lifelong antifungal therapy may be required 5

Patients with multiple Aspergillus nodules may benefit from antifungal treatment and require careful follow-up 4
For patients who fail therapy or develop triazole resistance, alternative options include intravenous micafungin, caspofungin, or amphotericin B, though with limited efficacy 5